Market Overview:
The global DNA repair drugs Market is estimated to be valued at US$ 762.7 Bn in 2023 and is expected to exhibit a CAGR of 32.4% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. DNA repair drugs are used to treat cancer by targeting DNA damage response pathways in cancer cells. They help enhance the efficacy of other anti-cancer therapies and radiotherapy.

Market key trends:
One of the key trends in the DNA repair drugs market is the increasing approval and launch of new drug molecules. For instance, in 2022, the US FDA approved Lynparza (olaparib) in combination with bevacizumab for the maintenance treatment of advanced ovarian cancer. In 2021, the FDA granted accelerated approval to Zejula (niraparib) for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Segment Analysis
The global DNA repair drugs market is segmented into DNA damage response drugs and DNA repair mechanism drugs. DNA damage response drugs dominated the market in 2017 as they play a crucial role in causing cell cycle arrest or apoptosis in cancerous cells with damaged DNA. This segment is expected to further bolster its dominance over the forecast period owing to the increasing demand for DNA damage response therapies in treating various cancers like breast cancer and lung cancer.

Key Takeaways
The global DNA Repair Drugs Market Growth is expected to witness high growth, exhibiting CAGR of 32.4% over the forecast period, due to increasing incidence of cancer globally.

Regional Analysis
North America dominated the global market in 2023 owing to rising prevalence of cancer, advanced healthcare infrastructure and availability of advanced treatments in the region. Europe stood as the second largest market. However, Asia Pacific is expected to be the fastest growing region due to increasing healthcare expenditure, rising awareness about cancer treatment and presence of developing economies like India and China in the region.

Key Players
Key players operating in the DNA repair drugs market are AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.

Read More:

https://www.blogger.com/blog/post/preview/6823004179658398383/7093993278970622560